Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study-Reference-Cited by-同舟云学术

Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study

Published:2016-10 Issue:10 Volume:47 Page:914-923
ISSN:2325-8160
Container-title:Ophthalmic Surgery, Lasers and Imaging Retina
language:en
Short-container-title:Ophthalmic Surg Lasers Imaging Retina

Author:

Wroblewski John J.,Hu Allen Y.

Publisher

SLACK, Inc.

Subject

Ophthalmology,Surgery

Reference37 articles.

1. Pegaptanib Sodium for Macular Edema Secondary to Central Retinal Vein Occlusion

2. Pegaptanib Sodium for Macular Edema Secondary to Branch Retinal Vein Occlusion

3. Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study: Bevacizumab for RVO long-term follow-up)

4. Bevacizumab Versus Ranibizumab in the Treatment of Macular Edema Due to Retinal Vein Occlusion: 6-Month Results of the CRAVE Study

5. Sustained Benefits from Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: 12-Month Outcomes of a Phase III Study

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diabetic retinopathy: Stressing the function of angiogenesis, inflammation and oxidative stress;Targeting Angiogenesis, Inflammation, and Oxidative Stress in Chronic Diseases;2024

2. Endothelial to mesenchymal cell transition in diabetic retinopathy: targets and therapeutics;Frontiers in Ophthalmology;2023-09-07

3. Topical Treatment for Retinal Degenerative Pathologies: A Systematic Review;International Journal of Molecular Sciences;2023-04-28

4. Inflammation in diabetic retinopathy: possible roles in pathogenesis and potential implications for therapy;Neural Regeneration Research;2023

5. Squalamines in Blockade of Tumor-Associated Angiogenesis and Cancer Progression;Cancers;2022-10-21